Status and phase
Conditions
Treatments
About
This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H&Y stage ≤2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Key Criteria:
Exclusion Key Criteria:
Primary purpose
Allocation
Interventional model
Masking
60 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Reference Study ID Number: BP43176 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal